摘要：近日，华中农业大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统 计出1项仪器设备采购意向，预算总额达1.65亿元。 近日，华中农业大学发布1项仪器设备采购意向，预算总额达1.65亿元，涉及空间组高分辨质谱仪、X射 线电子能谱仪、多维全息质谱联用仪、超高效液相色谱仪、体外DNA合成大片段导入系统（微操）、 三代纳米孔测序仪、细胞分析分选系统、无人机植物生理表型鉴定系统等仪器设备共计90台套，预计采 购时间为2026年3月。 详细采购清单： 华中农业大学2026年3月仪器设备采购意向汇总表 采购 需求概况 预算 采购 项目 国家基 础研究 创新提 升工程 设备更 新项目 （生物 学） 总投资16520万元，其中仪器设备购置费15996万元，占总投资的96.83%；工程建 设其他费及预备费524万元，占总投资的3.17%。本项目仪器设备购置主要包括近 红外成分分析仪、生物型原子力显微镜、高通量电转仪、核酸合成仪、高通量智 能人工气候室、空间组高分辨质谱仪、X射线电子能谱仪、多维全息质谱联用仪、 超高效液相色谱仪、体外DNA合成大片段导入系统（微操）、三代纳米孔测序 仪、细胞分析分选系统、 ...

摘要： 近日，华中农业大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统 计出1项仪器设备采购意向，预算总额达1.65亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日， 华中农业大学发布 1 项仪器设备采购意向，预算总额达 1 . 6 5 亿 元 ， 涉 及 空 间 组 高 分 辨质谱仪、X射线电子能谱仪、多维全息质谱联用仪、超高效液相色谱仪、体外DNA合成大片 段导入系统（微操）、三代纳米孔测序仪、细胞分析分选系统、无人机植物生理表型鉴定系统 等仪器设备共计9 0台套，预计采购时间为2 0 2 6 年 3 月。 详细采购清单： | | | | 采 | | --- | --- | --- | --- | | 采购 | | 预算 | 购 | | | 需求概况 | | | | 项目 | | 万元 | 时 | | | | | 间 | | 国家 | | | | | 基础 | 总投资16520万元，其中仪器设备购置费15996万元，占总投 | | | | 研究 | | | | | | 资的96.83%；工程建设其他费 ...

Project Overview - The project is titled "2025GC11 - First Batch Equipment Update Project of Southern Medical University" with a total budget of 33,136,000.00 CNY [3] - The procurement method is public bidding [3] Procurement Packages Package 1 - Budget: 630,000.00 CNY for a small animal three-dimensional behavior collection and analysis system [3] - Quantity: 1 unit [3] Package 2 - Budget: 3,280,000.00 CNY for a small animal spectral micro CT imaging platform [4] - Quantity: 1 set [4] Package 3 - Budget: 7,100,000.00 CNY for a small animal ultrasound photoacoustic bimodal imaging system [5] - Quantity: 1 set [5] Package 4 - Budget: 3,460,000.00 CNY for an inverted fluorescence microscope [6][7] - Quantity: 1 unit for each of the specified types [6][7] Package 5 - Budget: 5,870,000.00 CNY for laser confocal microscopes [8] - Quantity: 1 unit for each of the specified types [8] Package 6 - Budget: 480,000.00 CNY for a multifunctional enzyme labeler [9][10] - Quantity: 1 unit [9][10] Package 7 - Budget: 2,900,000.00 CNY for an imaging-type multifunctional microplate detection system [11] - Quantity: 1 unit for each of the specified types [11] Package 8 - Budget: 2,080,000.00 CNY for ultra-high performance liquid chromatography instruments [12][13] - Quantity: 1 unit for each of the specified types [12][13] Package 9 - Budget: 626,000.00 CNY for an ion chromatograph [14] - Quantity: 1 set [14] Package 10 - Budget: 2,080,000.00 CNY for a liquid chromatography-inductively coupled plasma mass spectrometer [15] - Quantity: 1 set [15] Package 11 - Budget: 4,630,000.00 CNY for fluorescence quantitative PCR instruments [16][17] - Quantity: 1 unit for each of the specified types [16][17] Document Acquisition - The bidding documents can be obtained online from October 31, 2025, to November 7, 2025, free of charge [18]

Core Viewpoint - Hefei University of Technology has announced multiple government procurement intentions for laboratory instruments, with a total budget of 118 million yuan, covering 19 items including advanced imaging and analysis systems, and high-performance laser equipment [1][2]. Procurement Overview - The procurement includes various high-end instruments such as low-field nuclear magnetic resonance imaging systems, whole slide scanners, ultra-high-performance liquid chromatography systems, rheometers, and extreme ultraviolet high-harmonic femtosecond lasers, with expected procurement time set for August to September 2025 [2][3][4][5]. Detailed Procurement List - The detailed procurement list includes: - Low-field nuclear magnetic resonance imaging analysis system: 4.63 million yuan - Whole slide scanner: 2.02 million yuan - Ultra-high-performance liquid chromatography system: 2.01 million yuan - Rheometer: 3.30 million yuan - High-speed coherent optical communication testing platform: 3.30 million yuan - Extreme ultraviolet high-harmonic femtosecond laser: 5.50 million yuan [7][8]. Instrument Specifications - Whole Slide Scanner: A high-end device for digital pathology, enabling automated scanning and stitching of glass slide samples into panoramic digital images, crucial for pathology diagnosis and research [3]. - Rheometer: A precision instrument for measuring the flow and deformation behavior of materials under stress, applicable in various fields including materials science and pharmaceuticals [4]. - Extreme Ultraviolet High-Harmonic Femtosecond Laser: An advanced light source capable of generating ultra-short coherent light pulses in the extreme ultraviolet range, used in ultrafast science and semiconductor testing [5]. Educational and Research Impact - The procurement aims to enhance the educational and research capabilities of Hefei University of Technology, supporting its status as a key institution in engineering and technology in China, with a focus on innovation and practical applications in various fields [12][13][14].

Core Insights - Konomai (Beijing) Technology Co., Ltd. has completed several million yuan in A+ round financing, led by Jiuan Medical, to accelerate commercialization and continue independent research and innovation [3] - The Chinese analytical instrument market heavily relies on imports, with annual import value around $100 billion, particularly in liquid chromatography as the leading product [3] - Konomai, established in 2019, focuses on the independent research and industrialization of ultra-high-performance liquid chromatography (UHPLC) technology, with a core founding team averaging nearly 20 years of experience in life science instruments [3][4] - The company has achieved a 95% localization rate for product components as of 2022, with a full series of UHPLC products developed [4] Company Performance - Since the start of its commercialization in 2023, Konomai has maintained an annual sales growth rate exceeding 50%, with overseas market growth surpassing 80% [5] - The company has expanded its customer base to hundreds across over 20 countries and regions, covering various fields such as drug analysis, biosynthesis, academic research, food safety, and environmental protection [5] Investment Perspective - Jiuan Medical's chairman, Liu Yi, emphasizes the focus on practical enterprises that can address industry pain points and lead industrial upgrades, highlighting Konomai's role in breaking the long-standing reliance on imports in the high-end market of ultra-high-performance liquid chromatography [6]

Core Viewpoint - The article highlights the significant advancements and growth of Konomai (Beijing) Technology Co., Ltd. in the high-end scientific instrument sector, particularly in the field of ultra-high-performance liquid chromatography (UHPLC), emphasizing its role in the domestic market's shift towards self-sufficiency and reduced reliance on imports [2][5]. Group 1: Company Overview - Konomai has completed a multi-million A+ round of financing led by Jiuan Medical, with funds aimed at accelerating commercialization and continuous innovation in independent research and development [2]. - Founded in 2019, Konomai focuses on the independent research and industrialization of UHPLC technology, with its core founding team averaging nearly 20 years of experience in the life science instrument field [2]. - The company has applied for over 30 patents and software copyrights, including 6 invention patents and 14 utility model patents, as of April 2025 [2]. Group 2: Product and Market Position - Konomai has achieved a 95% localization rate for its product components, significantly contributing to the reduction of procurement costs and enhancing analysis efficiency for clients [3]. - The company has launched a full series of UHPLC products, including automated IVD two-dimensional liquid chromatography systems and intelligent chromatography data management systems [2]. - Since initiating its commercialization strategy in 2023, Konomai has experienced a sales growth rate exceeding 50% annually, with international market growth surpassing 80% [3][4]. Group 3: Investment Perspective - Jiuan Medical's chairman, Liu Yi, emphasizes the importance of collaborating with practical enterprises that can address industry pain points and lead industrial upgrades, focusing on self-research and the domestic scientific instrument market [5]. - Konomai's advancements in the UHPLC sector are seen as pivotal in breaking the long-standing reliance on imports in China's high-end market [5].

Core Insights - Konomai has completed a strategic A+ round financing of several tens of millions, focusing on the R&D of high-end ultra-high-performance liquid chromatography (UHPLC) instruments to accelerate the domestic substitution process and build a comprehensive solution with a domestic component localization rate of 95% [1][2]. Technological Breakthroughs - Since its establishment in 2019, Konomai has focused on "positive independent R&D" and has become a leading enterprise in the domestic UHPLC technology field. The Frontier UHPLC system launched in 2023 has won multiple industry awards, including the BCEIA Gold Award. By 2025, the company aims to upgrade its ultra-high pressure dual pump UP26T and quad pump UP40, making it the second global manufacturer to achieve a pressure resistance of 20,000 psi (1380 Bar) [5][6]. Commercialization Strategy - Konomai has seen an average annual growth rate of over 50% since starting commercialization in 2023, with overseas market growth exceeding 80%. Its products are now available in over 20 countries and regions, serving hundreds of global clients. The company covers key areas such as drug analysis, biosynthesis, academic research, food safety, and environmental protection, helping clients reduce costs and improve efficiency through the localization of high-end equipment [6][7]. Capital Empowerment - Jiuan Medical's chairman, Liu Yi, emphasized that valuable investments are not just about capital accumulation but about collaborating with practical enterprises that can address industry pain points and lead industrial upgrades. The investment in Konomai is based on its ability to break the long-standing reliance on imports in the high-end UHPLC market, with Jiuan Medical aiming to leverage resource synergy and strategic empowerment to help Konomai overcome technical challenges and seize domestic substitution opportunities [7].

Core Insights - Konomai (Beijing) Technology Co., Ltd. has completed A+ round financing of several tens of millions, led by Jiuan Medical, to accelerate commercialization and continue independent R&D [1][2] - The Chinese analytical instrument market heavily relies on imports, with annual import value around $100 billion, particularly in liquid chromatography, which is the leading product in chemical analysis and life sciences [1] - Konomai, established in 2019, focuses on the independent R&D and industrialization of ultra-high-performance liquid chromatography (UHPLC) technology, with a core founding team averaging nearly 20 years of experience in life science instruments [1][2] Company Developments - Konomai has completed a full series layout of UHPLC products, including automated IVD two-dimensional liquid chromatography systems and intelligent chromatography data management systems [1] - The company has initiated the construction of a production base in Suzhou since 2022, achieving a domestic component localization rate of 95% [2] - Konomai's sales revenue has been growing at over 50% annually since the start of its commercialization layout in 2023, with overseas market growth exceeding 80% [2] Investment Perspective - Jiuan Medical aims to discover and collaborate with practical enterprises that can address industry pain points and lead industrial upgrades, focusing on deepening independent R&D and leveraging the "Stanford model" [3] - The company emphasizes the importance of the domestic scientific instrument localization trend and policy support to promote import substitution in the global market [3] - Konomai's breakthroughs in the UHPLC field are breaking the long-standing reliance on imports in China's high-end market [3]

Core Viewpoint - Jiangnan University has announced multiple government procurement intentions for laboratory instruments, with a total budget of 83.34 million yuan, covering 40 items including advanced analytical and testing equipment [2]. Summary by Categories Procurement Overview - The procurement plan includes a variety of sophisticated instruments such as intelligent biological manufacturing multi-scale analysis systems, atomic force microscopes, ultra-high performance liquid chromatography systems, and high-content imaging systems, with expected procurement time from March to October 2025 [2][4]. Specific Instruments and Their Functions - Intelligent Biological Manufacturing Multi-Scale Analysis System: Aimed at real-time monitoring and data integration for biological catalytic material synthesis and separation processes [4]. - Atomic Force Microscope: Designed for high-resolution 3D morphology testing and analysis of various material properties at micro and nano scales [4]. - Ultra-High Performance Liquid Chromatography Systems: Approximately three units will be procured for precise separation and quantitative analysis of various components in food and biological samples [5]. - Confocal Raman Spectrometer: Intended for non-destructive testing of food components and microstructural analysis, addressing urgent needs in food safety and quality control [5]. Budget and Timeline - The total budget for the procurement is 83.34 million yuan, with the procurement expected to take place between March and October 2025 [2][4].

Core Viewpoint - The article explores the historical development and breakthroughs in China's liquid chromatography industry, highlighting the contributions of key figures and the evolution of technology from its inception to the present day, emphasizing the importance of innovation and resilience in overcoming challenges [1][4][40]. Group 1: Historical Development - Liquid chromatography has evolved significantly since its inception in 1903, with the first commercial high-performance liquid chromatography (HPLC) instrument emerging in the late 1960s, marking its entry into laboratories [4][10]. - The first Chinese volume chromatography instrument was designed by Lu Peizhang in 1953, reducing the analysis time for petroleum samples from 30 hours to 1 hour, which was crucial for the development of the national industry [9][10]. - The establishment of the liquid chromatography discipline in China was marked by Lu Peizhang's presentation of the first gas chromatography report in 1956 [9][10]. Group 2: Key Figures and Their Contributions - Lu Peizhang, a pivotal figure in Chinese liquid chromatography, faced significant challenges in the 1950s due to a lack of resources and knowledge, yet he persevered to lay the foundation for the field [9][12]. - Zhang Yu-kui, a disciple of Lu Peizhang, embraced cutting-edge research and technology, contributing to the development of software for chromatographic analysis and becoming one of the first scientists in China to master programming [15][18]. - Li Tong, the founder of Yilit, was influenced by the teachings of Lu and Zhang, leading to the establishment of a successful liquid chromatography instrument manufacturing company that emphasizes user-centric product development [19][25]. Group 3: Technological Advancements and Market Position - Yilit has launched five generations of liquid chromatography products, with the latest, the EClassical 3200L, achieving recognition for its performance and stability, marking a significant step towards high-end domestic alternatives [29][32]. - The company maintains a commitment to R&D, investing over 10% of its annual sales in technological advancements, ensuring that its products meet the highest standards [27][30]. - The transition of Yilit's headquarters to Suzhou signifies a strategic shift towards high-end technology and international market expansion, aiming to enhance the global perception of Chinese instruments [35][39]. Group 4: Future Outlook and Challenges - The article emphasizes the need for continuous innovation and the adoption of new technologies to overcome international challenges and improve the global standing of Chinese liquid chromatography instruments [35][39]. - The next generation of leaders in the industry, such as Li Yabo, are focused on expanding product lines and deepening collaborations in biopharmaceuticals and clinical fields, indicating a forward-looking approach to growth [39][40]. - The legacy of resilience and innovation established by previous generations is crucial for the ongoing development of China's liquid chromatography sector, as it seeks to challenge established international brands [40][46].